Results 1 to 10 of about 97,617 (323)
Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach
Journal of Cardiothoracic Surgery, 2022 Background Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The
Sadia Hassan +2 more
doaj +2 more sources
Semin Intervent Radiol, 2022 AbstractEndovascular revascularization strategies have advanced tremendously over the years and are now often considered first line for treatment of peripheral arterial disease. Drug-eluting stents (DESs) have been developed as one of the tools to overcome the limitations of elastic recoil and neointimal hyperplasia observed with balloon angioplasty ...
Velagapudi C, Madassery S.
europepmc +3 more sources
Drug eluting stents in 2005 [PDF]
Heart, 2005 In the last 3–5 years there has been a major shift in the management of symptomatic, obstructive coronary artery disease, with a move from predominantly surgical to increasingly a percutaneous approach. The perceived benefits of percutaneous coronary intervention (PCI) include patient convenience, ease of service expansion, and the fact that more ...
Anthony Gershlick
openalex +4 more sources
Canadian Medical Association Journal, 2007 In their recent systematic review, Suzanne Ligthart and associates compared analyses of the cost-effectiveness of drug-eluting stents.[1][1] They found that in most studies in which an incremental cost-effectiveness ratio greater than $50 000 per quality-adjusted life-year was calculated the ...
Tangri N, Falcone El
+16 more sources
BMJ, 2006 Last week an expert panel of the US Food and Drug Administration (FDA) recommended that the FDA should issue warnings to doctors and patients about drug eluting coronary stents. The safety of such stents is unclear except in low risk patients. Furthermore, patients with drug eluting stents should take antiplatelet therapy for at least one year after ...
Gershlick, AH, Richardson, G
+13 more sources
A novel glycyrrhizin acid-coated stent reduces neointimal formation in a rabbit iliac artery model
Frontiers in Pharmacology, 2023 Introduction: Most drug-eluting stents (DESs) inhibit intimal hyperplasia but impair re-endothelialization. This study aimed to evaluate in vivo strut coverage and neointimal growth in a new glycyrrhizin acid (GA)-eluting stent.Methods: New Zealand White
Shuai Teng +6 more
doaj +1 more source
Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021 Background Percutaneous coronary intervention of calcified lesions was associated with worse outcomes in the era of bare‐metal and first‐generation drug‐eluting stents. Data on percutaneous coronary intervention of calcified lesions with newer‐generation
R. Hemetsberger +13 more
semanticscholar +1 more source
Frontiers in Cardiovascular Medicine, 2021 Background and Objectives: The second-generation drug-eluting stents have been used to treat chronic total occlusion lesion. However, there is limited evidence of the clinical outcomes that whether the second-generation drug-eluting stents is superior to
Xuan Qiao +5 more
doaj +1 more source
Drug-eluting stent thrombosis [PDF]
Therapeutic Advances in Cardiovascular Disease, 2009 Stent thrombosis is a rare complication following stent implantation; if it occurs, however, it is associated with a high morbidity and mortality. Despite reduced rates of restenosis, drug-eluting stents (DES) have not reduced the incidence of stent thrombosis as compared with bare-metal stents (BMS).
Stähli, B E, Camici, G G, Tanner, F C
openaire +3 more sources
Circulation, 2020 Supplemental Digital Content is available in the text. Background: Long-term comparative outcomes after percutaneous coronary intervention (PCI) with drug-eluting stents and coronary-artery bypass grafting (CABG) for left main coronary artery disease are
Duk‐Woo Park +17 more
semanticscholar +1 more source